The CGP is pleased to announce that Dr. Jonathan Kimmelman, a James McGill Professor and Director of both the Biomedical Ethics Unit and his own research group, STREAM (Studies in Translation, Ethics and Medicine) at McGill University’s Faculty of Medicine will be speaking at the CGP’s Summer Seminar Series on **Tuesday, August 20, 2019**. Everyone is encouraged to attend.

**Presentation by:** Dr. Jonathan Kimmelman  
**Date:** Tuesday, August 20, 2019  
**Time:** Noon – 1:00 p.m.  
**Where:** Strathcona Building, Lecture Hall – M-1

**Bio:** Jonathan Kimmelman, PhD, is a James McGill Professor and Director of both the Biomedical Ethics Unit and of his own research group, STREAM (Studies in Translation, Ethics and Medicine) at McGill University’s Faculty of Medicine. Dr. Kimmelman’s research centers on ethical, policy, and scientific dimensions of clinical development. In addition to his book, *Gene Transfer and the Ethics of First-in-Human Experiments* (Cambridge Press, 2010), major publications have appeared in *Science, JAMA, BMJ*, and *Hastings Center Report*. Dr. Kimmelman received the Maud Menten New Investigator Prize (2006), a CIHR New Investigator Award (2008), a Humboldt Bessel Award (2014), and was elected a Hastings Center Fellow (2018). He has sat on various advisory bodies within the U.S. NHLBI and NIAID, served for four tours of duty on U.S. National Academies of Medicine committees, and chaired the International Society of Stem Cell Research *Guidelines for Stem Cell Research and Clinical Translation* revision task force 2015-16. His research has been covered in major media outlets, including NPR’s *All Things Considered*, STATNews, and Nature. Dr. Kimmelman is Deputy Editor at *Clinical Trials* and serves as an Associate Editor at *PLoS Biology*.

**Title:** “Therapeutic value of accessing new drugs in clinical trials”

**Abstract:** Patients often pursue trial participation in order to access new drugs. In this talk, I will present several studies characterizing the level of benefit associated with accessing new treatments in phase 1 cancer trials, phase 2 cancer trials, combination therapy trials, and trials for neurodegenerative disease treatments. I will also discuss some of the ethical and normative implications for informed consent, risk/benefit analysis, and trial planning.